1-3 of 3
Sharon Yim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

Nirav N. Shah, Joanna C. Zurko, Dina Schneider, Sharon Yim, Mehdi Hamadani, Timothy S. Fenske, Bryon Johnson, Parameswaran Hari
Journal: Blood
Blood (2021) 138 (Supplement 1): 95.
https://doi.org/10.1182/blood-2021-146638
Published: 2021
Journal Articles

Quality of Life, Tryptophan Metabolites, and Neurotoxicity Assessments of Patients with Relapsed or Refractory B Cell Malignancies Undergoing CAR 20/19 - T Cell Therapy

Jennifer M Knight, MDMS, Igli Arapi, MSc, Aniko Szabo, PhD, Sharon Yim, BS, Garrett Sauber, BS, Cecilia Hillard, PhD, Parameswaran Hari, MD MRCP, Nirav N. Shah, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-141703
Published: 2020
Journal Articles

A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma

Nirav N Shah, MD, Fenlu Zhu, PhD, Carolyn Taylor, PhD, Dina Schneider, PhD, Winfried Krueger, Andrew Worden, Sharon Yim, Timothy S. Fenske, MD, Mehdi Hamadani, MD, Bryon Johnson, PhD, Boro Dropulic, PhD, Rimas Orentas, PhD, Parameswaran Hari, MBBS, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4193.
https://doi.org/10.1182/blood-2018-99-110194
Published: 2018